In septic rats, lenabasum reduced lung injury markers over 24 hours
Lenabasum attenuates CLP-induced sepsis-associated acute lung injury with coordinated modulation of redox balance and inflammation-resolution profile.
AI Summary
This animal study tested whether lenabasum, a selective CB2 receptor agonist, could lessen sepsis-associated acute lung injury. Thirty male rats were assigned to sham, sepsis, two lenabasum-dose, or dexamethasone groups; treatment was given after sepsis induction, and outcomes were assessed 24 hours later. The researchers measured lung oxidative and antioxidant markers, blood markers of inflammation and resolution, and lung tissue injury.
Compared with untreated septic rats, both lenabasum doses reduced several inflammatory markers and the lung injury score, while shifting lipoxin A4 toward sham levels. The higher dose also reduced lung reactive oxygen species, increased reduced glutathione, and was associated with less tissue injury. These early findings suggest lenabasum may affect both inflammation and redox balance in this rat model. This abstract-based summary cannot establish that the effects depend on CB2 receptors or that lenabasum is effective or safe in people; the authors call for further preclinical study.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Endocannabinoid levels differed in RA and tracked disease activity in women
Canine tumours show varied CB1 and CB2 expression; treatment effects remain…
Lab tests confirmed metabolites, some of which activated CB1
Explore More Research
Stay informed about the latest cannabis science.